Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a multi-component pharmaceutical mixture used as a peribulbar block for ophthalmic surgeries, specifically studied by **Cairo University** for managing postoperative pain. It consists of two local anesthetics, **lidocaine** and **bupivacaine**, which provide rapid-onset and long-acting regional anesthesia, respectively, by blocking voltage-gated sodium channels. **Hyaluronidase** is included as an enzymatic adjuvant to degrade hyaluronic acid in the extracellular matrix, thereby increasing tissue permeability and facilitating the spread of the anesthetic agents. **Ketorolac**, a non-steroidal anti-inflammatory drug (NSAID), is added to the mixture to enhance the quality of the block and provide prolonged postoperative analgesia by inhibiting prostaglandin synthesis through the inhibition of cyclooxygenase enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + lidocaine + bupivacaine + hyaluronidase.